


Mandatory Staging in Rectal Carcinoma

Gina Brown
Department of Radiology
Royal Marsden Hospital
Imperial College, London



Cuthbert Dukes 1932: Nodes as a prognostic factor



- A cases carcinoma is limited to the wall of the rectum, no extension into the extra-rectal tissues and no metastases in lymph nodes.
- B cases carcinoma has spread by direct continuity to the extra-rectal tissues but has not yet invaded the regional nodes,
- C cases metastases are present in the regional lymph nodes.
- system predicted <u>prognosis</u> and became a gold standard: Three-year survival after surgery was 80%, 73% and <u>7%</u> for A,B and C respectively.



There are big problems with the current TNM system and preoperative staging rectal cancer.....



The problems with TNM

- T3 category is enormous and survivals range from 90% (same as Dukes A) to 25%
- Stage III classification is too heterogeneous
- TNM does not take into account CRM status
- TNM does not take into account extramural vascular invasion
- TNM does not take into account low rectal cancer stage system
- Using T and N staging does not perform adequately in the assessment following neoadjuvant therapy



These tumours have entirely different prognostic outcomes


Stage II (T3N0)


Stage III (T3N1)

Stage I (T1N0)












NHS

mrT3dN0EMVI pos CRM+:CRT+chemo + beyond TME surgery





Current evidence base for preoperative local staging assessment using MRI




Cancer death in colorectal cancer

- Tumour present at the circumferential resection margins of the specimen
- Local recurrence
 - Survival <40%







First description of the mesorectal fascia using MRI. Brown G, Radiology 1999





First description of the meso MRI. Brown G, Radiology 199

The mesorectal fascia represents the potential CRM in patients undergoing TME. Clear demonstration of the mesorectal fascia by MRI enables prediction of final CRM status in patients having this operation. CRM involvement was predicted when tumour extended to within 1 mm of the mesorectal fascia on magnetic resonance images; while *British Journal of Surgery* 2003; 90: 355–364






First description of the meso The mesorectal fascia represents the potential CRM in

only 1mm cut-off on MRI predicts

local recurrence



E. Clear demonstration of the enables prediction of final CRM his operation. CRM involvement our extended to within 1 mm of nagnetic resonance images; while

; 90: 355-364



Firs MR Published Ahead of Print on November 25, 2013 as 10.1200/JCO.2012.45.3258 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.45.3258


JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

ential CRM in tration of the of final CRM I involvement ithin 1 mm of images; while

Preoperative Magnetic Resonance Imaging Assessment of Circumferential Resection Margin Predicts Disease-Free Survival and Local Recurrence: 5-Year Follow-Up Results of the MERCURY Study

Fiona G.M. Taylor, Philip Quirke, Richard J. Heald, Brendan J. Moran, Lennart Blomqvist, Ian R. Swift, David Sebag-Montefiore, Paris Tekkis, and Gina Brown





Firs MR Published Ahead of Print on November 25, 2013 as 10.1200/JCO.2012.45.3258 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.45.3258

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT


ential CRM in tration of the of final CRM

Conclusion


High-resolution MRI preoperative assessment of CRM status is superior to AJCC TNM-based criteria for assessing risk of LR, DFS, and OS. Furthermore, MRI CRM involvement is significantly associated with distant metastatic disease; therefore, colorectal cancer teams could intensify treatment and follow-up accordingly to improve survival outcomes.


J Clin Oncol 31. © 2013 by American Society of Clinical Oncology












30% of patients present with tumour involving mesorectal margins Preoperative CRT reduces this rate to 15% on post treatment MRI Persistence of ymrCRM involvement associated with 4 fold risk of local recurrence compared with ymrCRM clear







Guidelines

Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes

The Beyond TME Collaborative*

Correspondence to: Professor P. Tekkis, Department of Colorectal Surgery, Imperial College and the Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK (e-mail: p.tekkis@imperial.ac.uk)

Consensus abstract

Background: The management of primary rectal cancer beyond total mesorectal excision planes (PRC-bTME) and recurrent rectal cancer (RRC) is challenging. There is global variation in standards and no guidelines exist. To achieve cure most patients require extended, multivisceral, exenterative surgery, beyond conventional total mesorectal excision planes. The aim of the Beyond TME Group was to achieve consensus on the definitions and principles of management, and to identify areas of research priority.

Methods: Delphi methodology was used to achieve consensus. The Group consisted of invited experts

from surgery, radiology, oncology and pathology. The process included two international dedicated discussion conferences, formal feedback, three rounds of editing and two rounds of anonymized webbased voting. Consensus was achieved with more than 80 per cent agreement; less than 80 per cent agreement indicated low consensus. During conferences held in September 2011 and March 2012, open

Guidelines

Consensus statement on th patients with recurrent and mesorectal excision planes


The Beyond TME Collaborative*

Correspondence to: Professor P. Tekkis, Department of Colorectal S SW3 6JJ, UK (e-mail: p.tekkis@imperial.ac.uk)

Consensus abstract

Background: The management of primary rect bTME) and recurrent rectal cancer (RRC) is cl guidelines exist. To achieve cure most patient beyond conventional total mesorectal excision pl consensus on the definitions and principles of management, and to identify areas of research priority.

Anatomic compartments beyond TME: the exenterative compartments





Methods: Delphi methodology was used to achieve consensus. The Group consisted of invited experts from surgery, radiology, oncology and pathology. The process included two international dedicated discussion conferences, formal feedback, three rounds of editing and two rounds of anonymized webbased voting. Consensus was achieved with more than 80 per cent agreement; less than 80 per cent agreement indicated low consensus. During conferences held in September 2011 and March 2012, open

NHS

The Reval Manufacture

Disease affects central compartment

Above the peritoneal reflection within the pelvis

Disease is present/absent

Ureters are free of disease

Below the Peritoneum anteriorly

Bladder /Uterus/Vagina/Ovaries Prostate/Seminal vesicles/Urethra are free of disease

Posteriorly

The bony cortex/periosteum from S1-S2 is / is not involved by disease

The bony cortex/periosteum from S3-S5 /coccyx is/ is not involved by disease

Presacral fascia (\$1/\$2/\$3/\$4/\$5) is not involved by disease

Sciatic nerve/ S1/S2 nerve roots

No disease

Disease is present



NHS

Laterally

Pelvic fascia are free of disease

Pelvic sidewall compartment are free of disease

Internal/external iliac arterial/venous branches compartments

are free of disease

Sacrotuberous/sacrospinous

Piriformis/Obturator

Infralevatorcompartment

Levator muscles are free of disease Sphincter complex are free of disease

Anterior urogenital triangle/Perineum

Vaginal introitus/urethra : free of disease Retropubic space: : free of disease

Summary:

MRI Overall stage: T N M , [EMVI positive] [EMVI negative], [PSW positive] [PSW negative], Total number of compartments, Closest potential surgical margins are located, Resection would require:


ents beyond TME: compartments




priority.

ed experts dedicated nized web-0 per cent

agreement indicated low consensus. During conferences neighbors bettember 2011 and March 2012, open






3. Anatomic Surgical and Therapeutic Road Map




3. Anatomic Surgical and Mesorectal tascia and presacral fascia





3. Anatomic Surgical and Mesorectal tascia and

Rectosacral fascia





3. Anatomic Surgical and Mesorectal tascia and

Rectosacral fascia



Peritoneal reflection












NHS






3. Anatomic Surdical and




NHS

3. Anatomic Surdical and






3. Anatomic Surdical and



#3. Anatomic Surgical and Therapeutic Road Map



4. Staging and assessment of low rectal cancer








APE showing perforation just above level of levator insertion (red arrow)

Area of perforation lies in upper anal canal 42mm from anal verge Salerno et al BJS 2008










The triangle of "danger" - at or just above puborectalis sling

Tumour in this space results in TME plane CRM involvement

These tumours require ELAPE to avoid positive CRM


The outer 1mm of internal sphincter/muscularis (open arrow) must be free of tumour for plane to be safe -as the distal muscle tube forms the CRM in TME plane APE compared with ELAPE






LICAN er foundation

Inter-sphincteric APR



ent of

ent of





Staging nomenclature

- MRI Stage 1, tumor on MRI images appears confined to bowel wall but not through full thickness (with intact outer muscle coat).
- 2. MRI Stage 2, tumor on MRI replaces the muscle coat but does not extend into the intersphincteric plane.
- 3. MRI Stage 3, tumor on MRI invading into the intersphincteric plane or lying within 1mm of levator muscle.
- 4. MRI Stage 4, tumor invading into the external anal sphincter and infiltrating/extending beyond the levators +/- invading adjacent organ.







MRI prediction of outcome for low rectal cancer

TABLE 2. Resection margin status					
Patient characteristics	N	Positive margins	Negative margins	Odds ratio (95% CI)	P value (univariate)
All patients	101	27 (26.7%)	74 (73.3%)		
SHRI stage					< 0.001
1-2	54	3 (5.6%)	51 (94.4%)	1	
3-4	47	24 (51.1%)	23 (48.9)	17.7 (4.8-64.9)	
Quarient					0.026
Anteriora	49	18 (36.7%)	31 (63.3%)	2.8 (1.1-7)	
Posterior	52	9 (17.3%)	43 (82.7%)	1	
Operation					0.109
APE.	70	22 (31.4%)	48 (68.6%)	2.4 (0.8-7)	
LAR	31	5 (16.1%)	26 (83.9%)	1	
TRG					0.001
3-5	15	11 (73.3%)	4 (26.7%)	17.9 (2.7-116.9)	
1-2	15	2 (13.3%)	13 (86.7%)	1	
Prosperative treatment					0.557
Yes	55	16 (29.1%)	39 (70.9%)	1.305 (0.5-3.2)	
No	46	11 (23.9%)	35 (76.1%)	1	

Diseases Of The Colon & Rectum Volume 52: 4 (2009)





Assessed and clinically elicible (n+326) Excluded (nº 36) Cancer >6.0cm from anal verge on MRI (n+32) Milti no toleratedinot done (n=4) Not an adenocarcinoma (n=2) Dropouts (n=9) Deferral of Surgery (n=5) Palliative (no operation) (n=4) Low Rectal Cancer Assessed Clinically and by MRI (n=279) Safe MRI Low Rectal Unsafe MRI Low Rectal Plane (mrt.RP) (n=166) Plane (mrLRP) (n=113): No pre-operative Pre-operative therapy Pre-operative Therapy No Pre-operative therapy (n=88) A.b $(me23)^{AA}$ therapy (n=21) 4 (04/92) RESTAGE (mrTRG + ymrLRP) Operation (nxTE): Operation (net2): Operation (n=88): Operation (nv21): Good response* Poor response! No restaging MRI Anterior Resection (n+43) . Anterior Resection (n=00) (pCRM 0/33 - 0%) (pCRM 1546 - 23-91%) (pCRM 313 - 23-08%) Intersphinderic APE (nrd) International APE (n=4). . Anterior Resection (hmb): Anterior Resection In 31 · SAPE (nr10) Actorios Resuction inv 10h · Arterior Resector (n=8): • SAPE (m-6) . Intemphinateric APE (n=1): + \$876 (m4) · BLARE (NYS) Intersphinotesis APE (n=1) Interactionchair APE (serf) • BLAPE (m/54) • SAPE (text) · ELAPE (met): · SAPE (sell) SAPE (M2) Lecal (set). . ELAPE (sw10) Local (ref). Mostng (nr2): • BLAPE (re10) ELAPE IN 255 · Mosing (hrd): · Masing (n=1) . Exenteration (n=5): Exerteration (n=1) Lacetine To. Missing (n=2) Involved pCRM 288 (2:27%) Involved pCRM: 3/21 (14/28%) Involved pCRM: 14/92 (15:22%): Involved pCRM 6/78 (7-69%)





ent of

Findings



- Overall pCRM involvement was 9.0% [95% CI: 5.9– 12.3], significantly lower than previously reported rates of 30%.
- Patients with no adverse MRI features and a "safe" mrLRP underwent sphincter preserving surgery without preoperative radiotherapy, resulting in a 1.6% pCRM rate.
- The pCRM rate increased 5-fold for an "unsafe" compared with "safe" preoperative mrLRP [odds ratio (OR)=5.5; 95% CI, 2.3-13.3)].





#4. Staging and assessment of low rectal cancer

rates of 30%.

- Patients with no adverse MRI features and a "safe" mrLRP underwent sphincter preserving surgery without preoperative radiotherapy, resulting in a 1.6% pCRM rate.
- The pCRM rate increased 5-fold for an "unsafe"
- Battersby, N. J., How, P., Moran, B., Stelzner, S., West, N. P., Branagan, G. et al. MERCURY II Study Group. (2015).
- Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and
- Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study. *Ann Surg.* 2015






Limitations of the TNM – T3 category forms 80% of rectal cancers


 Jass (St Marks, UK) : – independent prognostic significance

 Harrison (Tennessee, USA): prognostic score depth of spread in mm


 Cawthorne (Guildford, UK): depth of spread significance


- Merkel and Hermanek (Erlangen, Germany)
 - T3 subclassification
 - T3a <1mm
 - T3b>1-5mm.
 - T3c>5-15mm
 - T3d>15mm (TNM staging system 1993 supplement)





"measuring extramural depth is the least subjective and most reliable of all the observations by radiologists"






295/311 (95 %) patients who underwent primary surgery.

The mean difference between MRI and histopathology assessment of tumor EMD was -0.046 mm, SD = 3.85 mm, the 95 % CI was -0.487 to 0.395 mm.

MRI and histopathology assessment of tumor spread are considered equivalent to within 0.5 mm (8R). Radiology 2007

"measuring extramural depth is the least subjective and

mrT3<5mm has same outcomes as pT2 tumours if mrCRM and mrEMVI negative Irrespective of N stage



diologists"



ment of 0.487 to

idered

equivalent to within 0.5 mm (eR). Radiology 2007

"measuring extramural depth is the least subjective and

The Regal Manda


mrT3<5mm h


Outcomes for MRI good prognosis rectal cancers: regardless of N stage

if mrC

TABLE 3. Outcomes for MRI-predicted Good Prognosis Patients and Effect of Univariate and Multivariate Analysis Local Recurrence, 5-year Overall Survival and Disease-free Survival

MERCURY-MRI-predicted Good Prognosis Patients	Local Recurrence	5-Year Overall Survival	5-Year Disease-free Survival
Total patients (n = 122)	3.3%	68.2% (95% CI, 60.3%-7.0%)	84.7% (95% CI, 76.0%-90.4%)
T3a/b N0, N1, and N2 (n = 58)	1.7%	67.9% (95% C1, 53.9%-78.5%)	81% (95% CI, 66.1%-89.8%)
T1,2, or, 3b, N positive disease (n = 22)	0%	81% (95% CL 48.7%-78.2%)	95% (95% CL 69.5%-99.3%) .






Taylor et al, MERCURY Annals of Surgery 2011


mrT3<5mm h Outcomes for MRI good prognosis rectal cancers: regardless of N stage

if mrC

TABLE 3. Outcomes for MRI-predicted Good Prognosis Patients and Effect of Univariate and Multivariate Analysis Local Recurrence, 5-year Overall Survival and Disease-free Survival

MERCURY-MRI-predicted Good Prognosis Patients	Local Recurrence	5-Year Overall Survival	5-Year Disease-free Survival
Total patients (n = 122)	3.3%	68.2% (95% CI, 60.3%-7.0%)	84.7% (95% CI, 76.0%-90.4%)
T3a/b N0, N1, and N2 (n = 58)	1.7%	67.9% (95% CI, 53.9%-78.5%)	81% (95% CI, 66.1%-89.8%)
T1,2, or, 3b, N positive disease (n = 22)	0%	81% (95% CI, 48.7%-78.2%)	95% (95% CI, 69.5%-99.3%) .






Taylor et al, MERCURY Annals of Surgery 2011

#6 An opportunity to identify Early Rectal Lesions suitable for local excision approach






T1: preservation of layer

hity to identify >3mm of muscularis and visible submucosal SIONS SUITADE on approach



able ach




= 5mm diameter
y preserved
uscle interface lost over 3mm
igle slice at 4 oclock
show smooth nodal capsule
geneity - benign
of 6.5 cm above anal verge and
outborectal is sling
ivenous invasion
otential focal early T2 invasion
e section







hity to identify able



= 5mm diameter
y preserved
uscle interface lost over 3n
ngle slice at 4 oclock
show smooth nodal capsula
geneity - benign
of 6.5 cm above analyerge
puborectalis sling
venous invasion
otential focal early T2 invaie section







SPECC Significant Polyp & Early Colorectal Cancer



able

MRI indications in ERC

- To assess bulky polyps >5mm thick
- Initial assessment of disease remote from the lumen within entire mesorectum
- · Identification of pelvic sidewall disease
- Road-mapping for surgical planning identify site location of stalk or invasive border and relationship to puborectalis sling, peritoneal reflection, mesorectal or intersphincteric border
- Identification of high risk patients with extramural venous invasion
- Ongoing surveillance of high risk cancer patients opting for conservative approach

SPECC|Significant Polyp & Early Colorectal Cancer

Discontinuous extramural venous spread - a poor prognostic factor


SPECC Significant Polyp & Early Colorectal Cance




able

MRI indications in ERC

- To assess bulky polyps >5mm thick
- Initial assessment of disease remote from the lumen within entire mesorectum
- Identification of pelvic sidewall disease
- Road-mapping for surgical planning identify site location
 - of stalk or invasive borde sling, peritoneal reflection border
- Identification of high risk invasion
- Ongoing surveillance of I for conservative approac











able


MRI indications in ERC


- To assess bulky polyps >5mm thick
- Initial assessment of disease remote from the lumen within entire mesorectum
- Identification of pelvic sidewall disease
- Road-mapping for surgical planning identify site location of stalk or invasive border






>1mm muscularis free of tumour 1mm deep muscle margin












#6 An opportunity to identify Early Rectal Lesions suitable for local excision approach







14113


Original article

Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging

G. Brown, A. G. Radeliffe, R. G. Newcombe, N. S. Dallimore, M. W. Bourne and G. T. Williams

Cardiff and the Vale NHS Trust, University of Wales College of Medicine, Carroyandrus in Di G. Brown, Department of Radiology, The Royal Matute-mail: gina-heowoffresh-indiames.nls.vik)

British Journal of Surgery 2003; 90: 355-364







Fig. 1 Extramural vascular invasion. a High-resolution T2-weighted fast spin-echo image and b corresponding histological (haematoxylin and eosin stained) whole-mount section. Tubular or serpiginous extension of tumour of intermediate signal intensity into perirectal fat corresponded to extramural venous invasion on histological examination. In this example, a tubular tongue of tumour extends into perirectal fat (arrow); foci of signal void indicate associated vessel (arrowheads). This appearance was confirmed as representing extramural venous spread on histological examination





Original article

Smith

The Royal Mandon

Preopera using high

G. Brown, A. C

Cardiff and the Vale : Carroyandour is: Dirte-mail: gins.hrowell

British Journa

onium .

MRI detected more persistent EMVI post CRT than pathology

	Group	Local/distan	Recurrence	p-v	14	- 6- C-			-Combat
	ypEMVI -	34/142	23.9%		0.8**	f.			ymrEMVI negative OFS 79.21
7,	ypEMVI •	20/46	43.5%	<0.05			1	_	(99% GI 70.0-88.4%)
71	ymrEhIVI -	23/89	25.8%		Service			٦,	
	ymrEMVI +	40/99	40.4%	<0.05	3				ymrEMV1 positive DFS 42.7% (95% CI 16.8-68.6%)
യ യാദ					0.24		(99 25.8%		
£ 32						yeartMV1 + 40	/99 40.4%		
					***	.00 vo.00	20 00	N-30	#0 00

Fig. 1 Extramura (haematoxylin as into perirectal fa extends into per representing ext





Chand M, Evans J, Swift RI, et al. Prognostic Significance of Postchemoradiotherapy High-Resolution MRI and Histopathology Detected Extramural Venous Invasion in Rectal Cancer. Ann Surg. 2014.


The Reyal Manufes

TABLE 4. Univariate and Multivariate Analysis (Cox Proportional Hazards for DFS) by Clinical, Preoperative MRI and Postoperative Histopathology Characteristics

633200		Group	Patient		Univariate Analysis			Multivariate Analysis		
Variables			Numbers	HR	95% CI	P	HR	95%-C1	P	
Patient characteristics	Sex	Female	67	Ref	3.50	800	Ref	No. September 1		
		Male	121	1.093	0.625-1.912	0.756	0.93	0.53-1.68	0.832	
	Height	Upper/mid	119	Ref			Ref			
	100000	Low	69	1.369	0.815-2.298	0.235	1.46	0.80-2.68	0.223	
Baseline MR staging	insT stage	Good	51	Ref			Ref			
		Poor	137	1.187	0.638-2.206	0.588	1.12	0.51-2.43	0.782	
	mtN stage	Negative	65	Ref			Ref			
		Positive -	123	1.196	0.691-2.071	0.523	1.72	0.90-3.28	0.199	
	mrEMVI	Negative	0.	Ref			Ref			
		Positive	188	0.902	0.527-1.544	0.706	0.89	0.42-1.89	0.078	
	mrCRM	Negative	107	Ref			Ref			
		Positive	81	0.846	0.497-1.441	0.539	0.85	0.44-1.62	0.617	
Post-CRT preoperative	ymrT stage	Good	116	Ref			Ref			
MR staging		Poor	72	1.218	0.723-2.052	0.459	1.01	0.54-1.89	0.984	
	ymrN stage.	Negative -	104	Ref			Ref			
	100	Positive	84	1.179	0.701-1.982	0.534	0.431	0.21-0.91	0.206	
	STORE MVI	Negative	8.9	Ref			Det	The second		
	-	Positive	99	1.987	1.237-4.323	0.004	(1.97	1.01-3.90	0:044	
	ymrCRM	Clear	148	Ref			Ref			
	122	Involved theratened	40	1.26	0.674-2.354	0.469	1.16	0.50-2.67	0.729	
Final pathology staging	ypT	Good	64	Ref			Ref			
	**	Poor	124	1.125	0.695-1.279	0.534	0.99	0.11-8.62	0.994	
	ypN.	Negative	118	Ref			Ref			
	- 1000	Positive	70	2.912	1.724-4.878	< 0.001	3.41	0.91-12.82	0.069	
	- interest	Negative	142	Ref			Rat-	1000	-	
		Positive	46	3.889	2.008-6.291	< 0.001	239	1.11-5.14	0.026	
	ypCRM	Negative	178	J Ref.			Ref			
		Positive	10	3.352	1.421-7.907	0.006	1.32	1.24-2.38	0.032	

#8.Lateral Pelvic Tumour Spread

The Regal Manufer








#8.Lateral Pelvic Tumour Spread


mrEMVI is associated with pelvic sidewall tumour deposits



#8.Lateral Pelvic Tumour Spread


mrEMVI is as sidewall

Preoperative risk factors associated with MRI pelvic sidewall nodes



Odds ratio	Р
3.64 (1.67, 7.94)	0.032
2.48 (1.08, 5.69)	0.001
0.85 (0.33, 2.17)	0.738
1.14 (0.64, 2.01)	0.663
1.72 (0.77, 3.86)	0.190
	3.64 (1.67, 7.94) 2.48 (1.08, 5.69) 0.85 (0.33, 2.17) 1.14 (0.64, 2.01)

How do we find tumours that require neoadjuvant therapy?



- Definition of mrCRM at risk
- Importance of mrT substage rather than stage
- The importance of MRI detected EMVI as a gold standard
- Prognostic importance of assessment of height and MRI low rectal stage
- Prognostic relevance of mrTRG
- Prognostic relevance of mucinous tumours
- examples of how MRI is being used for treatment stratification in clinical surgical and oncological trials

